
Oct 26 (Reuters) - Swiss drugmaker Novartis AG NOVN.S is close to acquiring U.S. biotech Avidity Biosciences RNA.O for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.
Reuters could not immediately confirm the report.